Kodiak Sciences Inc. $KOD Stake Boosted by UBS Group AG

UBS Group AG increased its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 197.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 168,562 shares of the company’s stock after purchasing an additional 111,853 shares during the quarter. UBS Group AG owned 0.32% of Kodiak Sciences worth $4,713,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in Kodiak Sciences during the fourth quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Kodiak Sciences during the fourth quarter worth $72,000. BNP Paribas Financial Markets lifted its stake in Kodiak Sciences by 89.4% during the third quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock worth $104,000 after purchasing an additional 3,009 shares during the last quarter. American Century Companies Inc. lifted its stake in Kodiak Sciences by 6.3% during the second quarter. American Century Companies Inc. now owns 79,745 shares of the company’s stock worth $297,000 after purchasing an additional 4,703 shares during the last quarter. Finally, Headlands Technologies LLC lifted its stake in Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Stock Performance

KOD stock opened at $37.41 on Friday. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -8.97 and a beta of 2.32. Kodiak Sciences Inc. has a 1 year low of $3.26 and a 1 year high of $47.84. The stock’s fifty day moving average is $37.26 and its two-hundred day moving average is $28.96.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.01). As a group, analysts predict that Kodiak Sciences Inc. will post -3.89 EPS for the current fiscal year.

Analyst Ratings Changes

KOD has been the topic of several research analyst reports. Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $14.00 to $61.00 in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. UBS Group raised their target price on Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Kodiak Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $42.14.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical?stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.